Revvity (RVTY) 10-Q 10 May 22 2022 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Apr. 03, 2022	May 05, 2022
Entity Listings [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Apr. 3, 2022
Document Transition Report	false
Entity File Number	001-5075
Entity Registrant Name	PERKINELMER, INC
Entity Incorporation, State or Country Code	MA
Entity Tax Identification Number	04-2052042
Entity Address, Address Line One	940 Winter Street,
Entity Address, City or Town	Waltham,
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	663-6900
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		126,148,473
Entity Central Index Key	0000031791
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Amendment Flag	false
Current Fiscal Year End Date	--01-01
PKI [Member]
Entity Listings [Line Items]
Trading Symbol	PKI
Trading Symbol	PKI
PKI 21A [Member]
Entity Listings [Line Items]
Trading Symbol	PKI 21A
Trading Symbol	PKI 21A
Common stock, $1 par value per share [Member]
Entity Listings [Line Items]
Title of 12(b) Security	Common stock, $1 par value per share
Title of 12(b) Security	Common stock, $1 par value per share
1.875% Notes due 2026 [Member]
Entity Listings [Line Items]
Title of 12(b) Security	1.875% Notes due 2026
Title of 12(b) Security	1.875% Notes due 2026
NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Listings [Line Items]
Security Exchange Name	NYSE
Security Exchange Name	NYSE

Condensed Consolidated Income S

Condensed Consolidated Income Statements - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Apr. 03, 2022	Apr. 04, 2021
Revenue from Contract with Customer, Excluding Assessed Tax	$ 1,259,442	$ 1,307,689
Cost of Goods and Services Sold	580,211	522,543
Selling, general and administrative expenses	334,393	251,410
Research and development expenses	76,609	60,216
Restructuring and other costs, net	13,384	5,744
Operating income from continuing operations	254,845	467,776
Interest And Other Expense Net	37,245	(12,706)
Income from continuing operations before income taxes	217,600	480,482
Provision for income taxes	40,597	101,139
Income from continuing operations	177,003	379,343
Loss on disposition of discontinued operations before income taxes	0	0
Provision for income taxes on discontinued operations and dispositions	41	38
Loss from discontinued operations and dispositions	(41)	(38)
Net income	$ 176,962	$ 379,305
Basic earnings (loss) per share:
Income (loss) from continuing operations (per share)	$ 1.40	$ 3.39
Gain (loss) on discontinued operations and dispositions (per share)	0	0
Net income (per share)	1.40	3.39
Diluted earnings (loss) per share:
Income (loss) from continuing operations (per share)	1.40	3.37
Gain (loss) on discontinued operations and dispositions (per share)	0	0
Net income (per share)	$ 1.40	$ 3.37
Weighted average shares of common stock outstanding:
Basic (in shares)	126,137	112,028
Diluted (in shares)	126,635	112,495
Cash dividends per common share	$ 0.07	$ 0.07
Product [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 866,945	$ 811,552
Cost of Goods and Services Sold	403,651	339,312
Service [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	392,497	496,137
Cost of Goods and Services Sold	$ 176,560	$ 183,231

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock Amount [Member]	Common Stock Amount [Member]Net Income [Member]	Common Stock Amount [Member]Other comprehensive loss [Member]	Common Stock Amount [Member]Dividends [Member]	Common Stock Amount [Member]Exercise of employee stock options and related income tax benefits [Member]	Common Stock Amount [Member]Purchases of common stock [Member]	Common Stock Amount [Member]Issuance of common stock for employee stock purchase plans [Member]	Common Stock Amount [Member]Issuance of common stock for long-term incentive program [Member]	Common Stock Amount [Member]Stock compensation [Member]	Capital In Excess of Par Value [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Common stock, Shares, Issued and outstanding		112,090,000
Beginning Balance at Jan. 03, 2021	$ 3,735,492	$ 112,090									$ 148,101	$ 3,507,262	$ (31,961)
Net income	379,305											379,305
Other comprehensive income (loss)	(72,211)
Dividends	(7,846)											(7,846)
Exercise of employee stock options and related income tax benefits	4,987	95									4,892
Issuance of common stock for employee benefit plans	(8)	0									(8)	0	0
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	(42,779)	(295)									(42,484)
Issuance of common stock for long-term incentive program	(4,450)	(176)									(4,274)
Stock compensation	899	0									899	0	0
Ending Balance at Apr. 04, 2021	4,002,305	112,066									115,690	3,878,721	(104,172)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	(72,211)												(72,211)
Beginning Balance at Jan. 03, 2021	3,735,492	112,090									148,101	3,507,262	(31,961)
Ending Balance at Jan. 02, 2022	$ 7,141,245	$ 126,241									2,760,522	4,417,174	(162,692)
Common stock, Shares, Issued and outstanding		112,066,000	0	0	0	95,000	(295,000)	0	176,000	0
Common stock, Shares, Issued and outstanding	126,241,000	126,241,000
Net income	$ 176,962											176,962
Other comprehensive income (loss)	(84,027)
Dividends	(8,905)											(8,905)
Exercise of employee stock options and related income tax benefits	1,397	$ 18									1,379
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations	(55,592)	(307)									(55,285)
Issuance of common stock for long-term incentive program	(12,470)	(188)									(12,282)
Stock compensation	2,792	0									2,792	0	0
Ending Balance at Apr. 03, 2022	7,186,342	$ 126,140									$ 2,721,690	$ 4,585,231	(246,719)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax	$ (84,027)												$ (84,027)
Common stock, Shares, Issued and outstanding	126,140,000	126,140,000	0	0	0	18,000	(307,000)		188,000	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2022	Apr. 04, 2021
Net income	$ 176,962	$ 379,305
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Foreign currency translation adjustments, net of income taxes	(84,011)	(72,305)
Unrealized (loss) gain on securities, net of income taxes	(16)	94
Other comprehensive loss	(84,027)	(72,211)
Comprehensive income	$ 92,935	$ 307,094

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Apr. 03, 2022	Jan. 02, 2022
Current assets:
Cash and cash equivalents	$ 669,755	$ 618,319
Accounts receivable, net	941,722	1,023,792
Inventories	645,924	624,714
Other current assets	197,110	173,955
Total current assets	2,454,511	2,440,780
Property, plant and equipment, net:
Property, plant and equipment, net	547,035	545,605
Operating Lease, Right-of-Use Asset	201,966	207,775
Intangible assets, net	3,942,878	4,063,104
Goodwill	7,367,284	7,416,584
Other assets, net	334,793	326,706
Total assets	14,848,467	15,000,554
Current liabilities:
Current portion of long-term debt	3,729	4,240
Accounts payable	376,694	355,458
Accrued expenses and other current liabilities	882,628	854,046
Total current liabilities	1,263,051	1,213,744
Long-term debt	4,863,978	4,979,737
Deferred taxes and long-term liabilities	1,354,991	1,480,469
Operating Lease, Liability, Noncurrent	180,105	185,359
Total liabilities	7,662,125	7,859,309
Commitments and contingencies (see Note 14)
Stockholders' equity:
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding	0	0
Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 126,140,000 shares and 126,241,000 shares at April 3, 2022 and January 2, 2022, respectively	126,140	126,241
Capital in excess of par value	2,721,690	2,760,522
Retained earnings	4,585,231	4,417,174
Accumulated other comprehensive loss	(246,719)	(162,692)
Total stockholders’ equity	7,186,342	7,141,245
Total liabilities and stockholders’ equity	$ 14,848,467	$ 15,000,554

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Apr. 03, 2022	Jan. 02, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 1	$ 1
Preferred stock, authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 1	$ 1
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	126,140,000	126,241,000
Common stock, Shares, Issued and outstanding	126,140,000	126,241,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2022	Apr. 04, 2021
Operating activities:
Net income	$ 176,962	$ 379,305
Loss from discontinued operations and dispositions, net of income taxes	41	38
Income from continuing operations	177,003	379,343
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:
Restructuring and other costs, net	13,384	5,744
Depreciation and amortization	120,052	70,186
Stock-based compensation	15,262	5,157
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	693	240
Amortization of deferred debt financing costs and accretion of discounts and debt extinguishment costs	1,900	896
Change in fair value of financial securities	12,125	(19,298)
Amortization of acquired inventory revaluation	16,868	2,981
Changes in operating assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested:
Accounts receivable, net	69,065	165,190
Inventories	(46,968)	(15,008)
Accounts payable	26,352	(5,048)
Increase (Decrease) in Accrued Expenses and Other	(122,521)	(116,883)
Net cash provided by operating activities	283,215	473,500
Investing activities:
Capital expenditures	(29,431)	(14,311)
Payments to Acquire Investments	(22,995)	(4,000)
Cash paid for acquisitions, net of cash, cash equivalents and restricted cash acquired	(3,880)	(443,543)
Net cash used in investing activities	(56,306)	(461,854)
Financing activities:
Payments of borrowings	220,000	743,545
Proceeds from borrowings	220,000	584,000
Repayments of Term Loan	(100,000)	0
Proceeds from sale of senior debt	0	799,856
Payments of debt financing and equity issuance costs	0	(7,882)
Settlement of cash flow hedges	(762)	6,005
Net payments on other credit facilities	(1,064)	(9,799)
Proceeds from issuance of common stock under stock plans	1,397	4,987
Purchases of common stock	(55,592)	(42,779)
Dividends paid	(8,837)	(7,852)
Net cash provided by (used in) financing activities	(164,858)	582,991
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	(10,636)	(6,849)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalent	51,415	587,788
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at beginning of period	619,337	402,613
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at end of period	670,752	990,401
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	669,755	988,234
Restricted Cash, Current	997	2,167
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 670,752	$ 990,401

Basis of Presentation

Basis of Presentation	3 Months Ended
	Apr. 03, 2022
Accounting Policies [Abstract]
Basis of Accounting [Text Block]	Basis of Presentation The condensed consolidated financial statements included herein have been prepared by PerkinElmer, Inc. (the “Company”), in accordance with accounting principles generally accepted in the United States of America (the “U.S.” or the "United States") and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information in the footnote disclosures of the financial statements has been condensed or omitted where it substantially duplicates information provided in the Company’s latest audited consolidated financial statements, in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes included in its Annual Report on Form 10-K for the fiscal year ended January 2, 2022, filed with the SEC (the “2021 Form 10-K”). The balance sheet amounts at January 2, 2022 in this report were derived from the Company’s audited 2021 consolidated financial statements included in the 2021 Form 10-K. The condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods indicated. The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts and classifications of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three months ended April 3, 2022 and April 4, 2021, respectively, are not necessarily indicative of the results for the entire fiscal year or any future period.

Revenue (Notes)

Revenue (Notes) - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2022	Apr. 04, 2021
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer [Text Block]	Revenue Disaggregation of revenue In the following tables, revenue is disaggregated by primary geographical markets, primary end-markets and timing of revenue recognition. Reportable Segments Three Months Ended April 3, 2022 April 4, 2021 Discovery & Analytical Solutions Diagnostics Total Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 273,158 $ 327,936 $ 601,094 $ 175,115 $ 400,927 $ 576,042 Europe 158,238 198,168 356,406 135,458 311,743 447,201 Asia 170,970 130,972 301,942 144,036 140,410 284,446 $ 602,366 $ 657,076 $ 1,259,442 $ 454,609 $ 853,080 $ 1,307,689 Primary end-markets Diagnostics $ — $ 657,076 $ 657,076 $ — $ 853,080 $ 853,080 Life sciences 412,409 — 412,409 277,201 — 277,201 Applied markets 189,957 — 189,957 177,408 — 177,408 $ 602,366 $ 657,076 $ 1,259,442 $ 454,609 $ 853,080 $ 1,307,689 Timing of revenue recognition Products and services transferred at a point in time $ 461,314 $ 554,520 $ 1,015,834 $ 326,662 $ 615,106 $ 941,768 Services transferred over time 141,052 102,556 243,608 127,947 237,974 365,921 $ 602,366 $ 657,076 $ 1,259,442 $ 454,609 $ 853,080 $ 1,307,689 Major Customer Concentration Revenues from one customer in the Company's Diagnostics segment represent approximately $112.7 million and $205.6 million of the Company's total revenue for the three months ended April 3, 2022 and April 4, 2021, respectively. On March 31, 2022, the Company was notified by the California Department of Public Health (“CDPH”) that, due to the decrease in COVID-19 cases and the related decreased need for testing for COVID-19, the CDPH intends to end its contract with the Company for the supply and operation of the Valencia Branch Laboratory effective on May 15, 2022. The Company shall recognize the unamortized contract liability pertaining to the nonrefundable prepayment as revenue over the remaining period through May 15, 2022. As of March 31, 2022, the unamortized contract liability was $126.2 million . The contract liability that the Company expects to recognize in revenue in the second quarter of fiscal year 2022 amounts to $117.8 million . Contract Balances Contract assets: The unbilled receivables (contract assets) primarily relate to the Company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are transferred to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the condensed consolidated balance sheets. (In thousands) Balance at January 2, 2022 $ 72,117 Transferred to trade receivables from unbilled receivables recognized at the beginning of the period (37,062) Increases as a result of recognition of revenue before billing to customers, excluding amounts transferred to trade receivables during the period 27,156 Balance at April 3, 2022 $ 62,211 Contract liabilities: The contract liabilities primarily relate to the advance consideration received from customers for products and related services for which transfer of control has not occurred at the balance sheet date. Contract liabilities are classified as either current in "Accounts payable" or "Accrued expenses and other current liabilities" or as long-term in "Long-term liabilities" in the condensed consolidated balance sheets based on the timing of when the Company expects to recognize revenue. (In thousands) Balance at January 2, 2022 $ 201,073 Revenue recognized that was included in the contract liability balance at the beginning of the period (57,691) Increases due to cash received, excluding amounts recognized as revenue during the period 28,486 Balance at April 3, 2022 $ 171,868
Revenue from Contract with Customer, Excluding Assessed Tax	$ 1,259,442	$ 1,307,689
Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	1,015,834	941,768
Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	243,608	365,921
Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	601,094	576,042
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	356,406	447,201
Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	301,942	284,446
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	657,076	853,080
Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	412,409	277,201
Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	189,957	177,408
Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	602,366	454,609
Discovery & Analytical Solutions [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	461,314	326,662
Discovery & Analytical Solutions [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	141,052	127,947
Discovery & Analytical Solutions [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	273,158	175,115
Discovery & Analytical Solutions [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	158,238	135,458
Discovery & Analytical Solutions [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	170,970	144,036
Discovery & Analytical Solutions [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Discovery & Analytical Solutions [Member] | Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	412,409	277,201
Discovery & Analytical Solutions [Member] | Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	189,957	177,408
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	657,076	853,080
Diagnostics [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	554,520	615,106
Diagnostics [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	102,556	237,974
Diagnostics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	327,936	400,927
Diagnostics [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	198,168	311,743
Diagnostics [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	130,972	140,410
Diagnostics [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	657,076	853,080
Diagnostics [Member] | Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Diagnostics [Member] | Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 0	$ 0

Business Combinations

Business Combinations	3 Months Ended
	Apr. 03, 2022
Business Combinations [Abstract]
Business Combinations	Business Combinations Acquisitions in fiscal year 2022 During the first quarter of fiscal year 2022, the Company completed the acquisition of two businesses for aggregate consideration of $13.5 million. Identifiable definite-lived intangible assets, such as core technology, acquired as part of these acquisitions had a weighted average amortization period of 5 years. Acquisitions in fiscal year 2021 Acquisition of BioLegend, Inc. In fiscal year 2021, t he Company completed the acquisition of BioLegend, Inc. ("BioLegend") and paid an aggregate consideration of $5.7 billion, net of cash acquired of $292.4 million, reflecting working capital and other adjustments (the "Aggregate Consideration"). The Aggregate Consideration was paid in a combination of $3.3 billion in cash and shares of the Company's common stock having a fair value of approximately $2.6 billion based on the $187.56 per share closing price of the Company's common stock on the New York Stock Exchange on September 17, 2021 (the "Stock Consideration"). The Stock Consideration consisted of 14,066,799 shares of the Company's common stock. BioLegend is recognized as a leading, global provider of life science antibodies and reagents, headquartered in San Diego, California, with approximately 700 employees. The operations for this acquisition is reported within the results of the Company's Discovery & Analytical Solutions segment from the acquisition date. The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and is not tax deductible. Identifiable definite-lived intangible assets, such as core technology, trade names, customer relationships and clone library, acquired as part of this acquisition had a weighted-average amortization period of 16.3 years. BioLegend's revenue and net loss from the acquisition date to January 2, 2022 were $91.7 million and $25.8 million, respectively. The net loss includes $47.0 million of amortization of intangible assets recognized in the acquisition as well as $16.6 million of amortization of fair value adjustment to acquired inventory. The following unaudited pro forma information presents the combined financial results for the Company and BioLegend as if the acquisition of BioLegend had been completed at the beginning of fiscal year 2020: Three Months Ended (In thousands, except per share data) Pro Forma Statement of Operations Information: Revenue $ 1,385,114 Income from continuing operations $ 370,624 Basic earnings per share: Income from continuing operations $ 2.94 Diluted earnings per share: Income from continuing operations $ 2.93 The unaudited pro forma information for the first quarter of fiscal year 2021 has been calculated after applying the Company's accounting policies and the impact of acquisition date fair value adjustments. These pro forma condensed consolidated financial results have been prepared for comparative purposes only and include certain adjustments, such as increased interest expense on debt obtained to finance the transaction, and increased amortization for the fair value of acquired intangible assets. The pro forma information does not reflect the effect of costs or synergies that would have been expected to result from the integration of the acquisition. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the combination occurred at the beginning of the period presented, or of future results of the consolidated entities. The actual results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors. Other acquisitions in 2021. During fiscal year 2021, the Company also completed t he acquisition of seven other businesse s for aggregate consideration of $1.2 billion. The acquired businesses include Oxford Immunotec Global PLC, a company based in Abingdon, UK with approximately 275 employees, for total consideration of $590.9 million and Nexcelom Bioscience Holdings, LLC, a company based in Lawrence, Massachusetts with approximately 130 employees, for total consideration of $267.3 million, and five other businesses, which were acquired for total consideration of $318.6 million. The excess of the purchase prices over the fair values of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as employee workforces acquired, and has been allocated to goodwill, which is not tax deductible. Identifiable definite-lived intangible assets, such as core technology, trade names, and customer relationships, acquired as part of these acquisitions had a weighted-average amortization period of 12.3 years. The total purchase price for the acquisitions in fiscal year 2021 has been allocated to the estimated fair value of assets acquired and liabilities assumed as follows: BioLegend Other (In thousands) Fair value of business combination: Cash payments $ 3,336,115 1,128,584 Common stock issued 2,638,369 — Other liability 6,857 2,910 Contingent consideration — 45,031 Working capital and other adjustments — 183 Less: cash acquired (292,377) (195,010) Total $ 5,688,964 $ 981,698 Identifiable assets acquired and liabilities assumed: Current assets $ 184,704 $ 72,104 Property, plant and equipment 147,200 26,507 Other assets 9,330 15,564 Identifiable intangible assets: Core technology and clone library 782,400 290,089 Trade names and patents 38,000 39,626 Licenses 8,979 — Customer relationships and backlog 1,714,800 141,670 Goodwill 3,510,710 550,023 Deferred taxes (668,920) (86,100) Deferred revenue — (1,197) Debt assumed — (4,628) Liabilities assumed (38,239) (61,960) Total $ 5,688,964 $ 981,698 The preliminary allocations of the purchase prices for acquisitions are based upon initial valuations. The Company's estimates and assumptions underlying the initial valuations are subject to the collection of information necessary to complete its valuations within the measurement periods, which are up to one year from the respective acquisition dates. The primary areas of the preliminary purchase price allocations that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired and liabilities assumed, assets and liabilities related to income taxes and related valuation allowances, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair values of the net assets acquired at the acquisition dates during the measurement periods. During the measurement periods, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition dates that, if known, would have resulted in the recognition of those assets and liabilities as of those dates. These adjustments will be made in the periods in which the amounts are determined and the cumulative effect of such adjustments will be calculated as if the adjustments had been completed as of the acquisition dates. All changes that do not qualify as adjustments made during the measurement periods are also included in current period earnings. There were no material measurement period adjustments recognized in the current period. The allocations of the purchase prices for acquisitions are based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization of the purchase price allocations. The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. As of April 3, 2022, the Company may have to pay contingent consideration related to acquisitions with open contingency periods of up to $111.3 million. As of April 3, 2022, the Company has recorded contingent consideration obligations of $49.8 million, of which $1.1 million was recorded in accrued expenses and other current liabilities, and $48.7 million was recorded in long-term liabilities. As of January 2, 2022, the Company had recorded contingent consideration obligations with an estimated fair value of $58.0 million, of which $1.3 million was recorded in accrued expenses and other current liabilities, and $56.7 million was recorded in long-term liabilities. The expected maximum earnout period for acquisitions with open contingency periods does not exceed 6.7 years from April 3, 2022, and the remaining weighted average expected earnout period at April 3, 2022 was 5.7 years. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the condensed consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of definite-lived intangible assets or the recognition of additional contingent consideration which would be recognized as a component of operating expenses from continuing operations. Total acquisition and divestiture-related costs for the three months ended April 3, 2022 and April 4, 2021 were $20.5 million and $4.4 million, respectively. These amounts included $7.5 million of stock compensation expense related to awards given to BioLegend employees for the three months ended April 3, 2022 and $5.4 million of net foreign exchange gain related to the Company's acquisition of Oxford and $5.4 million of incentive award associated with the Company's acquisition of Meizheng Group for the three months ended April 4, 2021. These acquisition and divestiture-related costs were expensed as incurred and recorded in selling, general and administrative expenses and interest and other expense, net in the Company's condensed consolidated statements of operations.

Restructuring and Lease Charges

Restructuring and Lease Charges, Net	3 Months Ended
	Apr. 03, 2022
Restructuring and Related Activities [Abstract]
Restructuring and Lease Charges, Net	Restructuring and Other Costs, Net The Company implemented a restructuring plan in the first quarter of fiscal year 2022 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives and integrate new acquisitions (the "Q1 2022 Plan"). The Company implemented restructuring plans in each quarter of fiscal year 2021 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives and integrate new acquisitions (the "Q1 2021 Plan", "Q2 2021 Plan", "Q3 2021 Plan" and "Q4 2021 Plan", respectively). Details of the plans initiated in previous years (the “Previous Plans”) are discussed more fully in Note 4, Restructuring and Other Costs, Net, to the audited consolidated financial statements in the 2021 Form 10-K. The following table summarizes the reductions in headcount, the initial restructuring or contract termination charges by reporting segment, and the dates by which payments were substantially completed, or the dates by which payments are expected to be substantially completed, for restructuring actions implemented during fiscal years 2022 and 2021: Workforce Reductions Closure of Excess Facility Total (Expected) Date Payments Substantially Completed by Headcount Reduction Discovery & Analytical Solutions Diagnostics Discovery & Analytical Solutions Diagnostics Severance Excess Facility (In thousands, except headcount data) Q1 2022 Plan 81 $ 5,832 $ 399 $ — $ — $ 6,231 Q4 FY2022 — Q4 2021 Plan 31 3,139 77 150 — 3,366 Q3 FY2022 Q1 FY2023 Q3 2021 Plan 39 420 366 — — 786 Q2 FY2022 — Q2 2021 Plan 25 968 564 — — 1,532 Q1 FY2022 — Q1 2021 Plan 77 3,941 1,615 — — 5,556 Q4 FY2021 — The Company has terminated various contractual commitments in connection with certain disposal activities and has recorded charges for the costs of terminating these contracts before the end of their terms and the costs that will continue to be incurred for the remaining terms without economic benefit to the Company. The Company recorded net pre-tax charges of $6.3 million in the Discovery & Analytical Solutions segment during the three months ended April 3, 2022 as a result of these contract terminations. The Company recorded net pre-tax gains of $0.4 million in the Diagnostics segment during the three months ended April 3, 2022 as a result of changes in estimates from prior contract terminations. The Company recorded pre-tax charges of $1.3 million and $0.2 million associated with relocating facilities during the three months ended April 3, 2022 and April 4, 2021, respectively, in the Discovery & Analytical Solutions segment. The Company expects to make payments on these relocation activities through end of fiscal year 2022.

Interest and Other Expense (Inc

Interest and Other Expense (Income), Net	3 Months Ended
	Apr. 03, 2022
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and Other Expense, Net Interest and other expense, net, consisted of the following: Three Months Ended April 3, April 4, (In thousands) Interest income $ (595) $ (411) Interest expense 28,388 14,126 Change in fair value of financial securities 12,125 (19,298) Other components of net periodic pension credit (2,362) (3,719) Other income, net (311) (3,404) Total interest and other expense (income), net $ 37,245 $ (12,706)

Inventories, Net

Inventories, Net	3 Months Ended
	Apr. 03, 2022
Inventory Disclosure [Abstract]
Inventories, Net	Inventories Inventories consisted of the following: April 3, January 2, (In thousands) Raw materials $ 239,937 $ 229,356 Work in progress 77,667 69,744 Finished goods 328,320 325,614 Total inventories $ 645,924 $ 624,714

Debt

Debt	3 Months Ended
	Apr. 03, 2022
Debt Disclosure [Abstract]
Debt	Debt The Company’s debt consisted of the following: April 3, Outstanding Principal Unamortized Debt Discount Unamortized Debt Issuance Costs Net Carrying Amount (In thousands) Long-Term Debt: Senior Unsecured Revolving Credit Facility $ — $ — $ (3,181) $ (3,181) Unsecured Term Loan Credit Facility 400,000 — (477) 399,523 0.550% Senior Unsecured Notes due in 2023 ("2023 Notes") 500,000 (131) (1,798) 498,071 0.850% Senior Unsecured Notes due in 2024 ("2024 Notes") 800,000 (408) (4,519) 795,073 1.875% Senior Unsecured Notes due in 2026 ("2026 Notes") 551,800 (2,341) (2,155) 547,304 1.900% Senior Unsecured Notes due in 2028 ("2028 Notes") 500,000 (338) (4,078) 495,584 3.3% Senior Unsecured Notes due in 2029 ("2029 Notes") 850,000 (2,199) (6,086) 841,715 2.55% Senior Unsecured Notes due in March 2031 ("March 2031 Notes") 400,000 (123) (3,227) 396,650 2.250% Senior Unsecured Notes due in September 2031 ("September 2031 Notes") 500,000 (1,458) (4,302) 494,240 3.625% Senior Unsecured Notes due in 2051 ("2051 Notes") 400,000 (4) (4,333) 395,663 Other Debt Facilities, non-current 3,336 — — 3,336 Total Long-Term Debt $ 4,905,136 $ (7,002) $ (34,156) $ 4,863,978 Current Portion of Long-term Debt: Other Debt Facilities, current 3,729 — — 3,729 Total $ 4,908,865 $ (7,002) $ (34,156) $ 4,867,707 January 2, Outstanding Principal Unamortized Debt Discount Unamortized Debt Issuance Costs Net Carrying Amount (In thousands) Long-Term Debt: Senior Unsecured Revolving Credit Facility $ — $ — $ (3,362) $ (3,362) Unsecured Term Loan Credit Facility 500,000 (14) (658) 499,328 2023 Notes 500,000 (152) (2,093) 497,755 2024 Notes 800,000 (447) (4,945) 794,608 2026 Notes 568,600 (2,538) (2,280) 563,782 2028 Notes 500,000 (348) (4,200) 495,452 2029 Notes 850,000 (2,252) (6,234) 841,514 March 2031 Notes 400,000 (126) (3,294) 396,580 September 2031 Notes 500,000 (1,485) (4,380) 494,135 2051 Notes 400,000 (4) (4,335) 395,661 Other Debt Facilities, non-current 4,284 — — 4,284 Total Long-Term Debt $ 5,022,884 $ (7,366) $ (35,781) $ 4,979,737 Current Portion of Long-term Debt: Other Debt Facilities, current 4,240 — — 4,240 Total $ 5,027,124 $ (7,366) $ (35,781) $ 4,983,977

Earnings Per Share

Earnings Per Share	3 Months Ended
	Apr. 03, 2022
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations: Three Months Ended April 3, April 4, (In thousands) Number of common shares—basic 126,137 112,028 Effect of dilutive securities: Stock options 339 359 Restricted stock awards 159 108 Number of common shares—diluted 126,635 112,495 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 512 162 Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future.

Industry Segment Information

Industry Segment Information	3 Months Ended
	Apr. 03, 2022
Segment Reporting [Abstract]
Industry Segment Information	Segment InformationThe Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1, Nature of Operations and Accounting Policies, to the audited consolidated financial statements in the 2021 Form 10-K. The principal products and services of the Company's two operating segments are: • Discovery & Analytical Solutions . Provides products and services targeted towards the life sciences and applied markets. • Diagnostics . Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets. The Diagnostics segment serves the diagnostics market. The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments. Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below: Three Months Ended April 3, April 4, (In thousands) Discovery & Analytical Solutions Product revenue $ 408,875 $ 267,255 Service revenue 193,491 187,354 Total revenue 602,366 454,609 Operating income from continuing operations 14,515 42,947 Diagnostics Product revenue 458,070 544,297 Service revenue 199,006 308,783 Total revenue 657,076 853,080 Operating income from continuing operations 258,012 441,467 Corporate Operating loss from continuing operations (17,682) (16,638) Continuing Operations Product revenue 866,945 811,552 Service revenue 392,497 496,137 Total revenue 1,259,442 1,307,689 Operating income from continuing operations 254,845 467,776 Interest and other expense (income), net 37,245 (12,706) Income from continuing operations before income taxes $ 217,600 $ 480,482

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Apr. 03, 2022
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity Comprehensive Income: The components of accumulated other comprehensive loss consisted of the following: April 3, January 2, (In thousands) Foreign currency translation adjustments, net of income taxes $ (245,821) $ (161,810) Unrecognized prior service costs, net of income taxes (842) (842) Unrealized net losses on securities, net of income taxes (56) (40) Accumulated other comprehensive loss $ (246,719) $ (162,692) Stock Repurchases: On July 31, 2020, the Company's Board of Directors (the "Board") authorized the Company to repurchase shares of common stock for an aggregate amount up to $250.0 million under a stock repurchase program (the "Repurchase Program"). The Repurchase Program will expire on July 27, 2022 unless terminated earlier by the Board and may be suspended or discontinued at any time. During the three months ended April 3, 2022, the Company repurchased 240,000 shares of common stock under the Repurchase Program for an aggregate cost of $43.4 million. As of April 3, 2022, $144.0 million remained available for aggregate repurchases of shares under the Repurchase Program. In addition, the Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company's equity incentive plans. During the three months ended April 3, 2022, the Company repurchased 67,107 shares of common stock for this purpose at an aggregate cost of $12.2 million. The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value. Dividends: The Board declared a regular qua rterly cash dividend of $0.07 per share for the first quarter of fiscal year 2022 and in each quarter of fiscal year 2021. At April 3, 2022, the Company had accrued $8.8 million for dividends declared on January 27, 2022 for the first quarter of fiscal year 2022 that will be paid on May 13, 2022. On April 28, 2022, the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the second quarter of fiscal year 2022 that will be payable in August 2022. In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	3 Months Ended
	Apr. 03, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net The Company tests goodwill and non-amortizing intangible assets at least annually for possible impairment. Accordingly, the Company completes the annual testing of impairment for goodwill and non-amortizing intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or non-amortizing intangible assets. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill . The Company performed its annual impairment testing for its reporting units as of January 3, 2022, its annual impairment testing date for fiscal year 2022. The Company concluded that there was no goodwill impairment, and the fair value exceeded the carrying value by more than 20% for each reporting unit. F or the fiscal year 2022 impairment analysis, t he range of the long-term terminal growth rates for the Compa ny’s reporting units was 2% to 5% and the range of the discount rates for the reporting units was 7% to 11.5%. Keeping all other variables constant, a 10% change in any one of these input assumptions for the various reporting units would still allow the Company to conclude that there was no impairment of goodwill. The Company has consistently employed the income approach to estimate the current fair value when testing for impairment of goodwill. A number of significant assumptions and estimates are involved in the application of the income approach to forecast operating cash flows, including markets and market share, sales volumes and prices, costs to produce, tax rates, capital spending, discount rates and working capital changes. Cash flow forecasts are based on approved business unit operating plans for the early years’ cash flows and historical relationships in later years. The income approach is sensitive to changes in long-term terminal growth rates and the discount rates. The long-term terminal growth rates are consistent with the Company’s historical long-term terminal growth rates, as the current economic trends are not expected to affect the long-term terminal growth rates of the Company. The Company corroborates the income approach with a market approach. The changes in the carrying amount of goodwill for the three months ended April 3, 2022 were as follows: Discovery & Analytical Solutions Diagnostics Consolidated (In thousands) Balance at January 2, 2022 $ 5,446,234 $ 1,970,350 $ 7,416,584 Foreign currency translation (38,132) (13,795) (51,927) Acquisitions, earn-outs and other (1,085) 3,712 2,627 Balance at April 3, 2022 $ 5,407,017 $ 1,960,267 $ 7,367,284 Identifiable intangible asset balances by category were as follows: April 3, January 2, (In thousands) Patents $ 31,025 $ 31,033 Less: Accumulated amortization (28,742) (28,693) Net patents 2,283 2,340 Trade names and trademarks 168,225 170,983 Less: Accumulated amortization (64,762) (62,441) Net trade names and trademarks 103,463 108,542 Licenses 68,001 67,887 Less: Accumulated amortization (54,897) (54,315) Net licenses 13,104 13,572 Core technology 1,841,179 1,834,177 Less: Accumulated amortization (527,001) (494,310) Net core technology 1,314,178 1,339,867 Customer relationships 3,165,411 3,195,704 Less: Accumulated amortization (726,145) (673,425) Net customer relationships 2,439,266 2,522,279 In-process research and development — 5,920 Net amortizable intangible assets 3,872,294 3,992,520 Non-amortizing intangible asset: Trade name 70,584 70,584 Total $ 3,942,878 $ 4,063,104

Derivatives And Hedging Activit

Derivatives And Hedging Activities	3 Months Ended
	Apr. 03, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Hedging Activities	Derivatives and Hedging ActivitiesThe Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 60% of the Company’s business is conducted outside of the United States, generally in foreign currencies. As a result, fluctuations in foreign currency exchange rates can increase the costs of financing, investing and operating the business. In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity, and are recorded at fair value on the Company’s condensed consolidated balance sheets. The unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from operating activities within the Company’s condensed consolidated statement of cash flows. Principal hedged currencies include the Chinese Renminbi, British Pound, Euro, Singapore Dollar and Swedish Krona. The Company held forward foreign exchange contracts, designated as economic hedges, with U.S. dollar equivalent notional amounts totaling $376.6 million, $371.9 million and $969.5 million at April 3, 2022, January 2, 2022 and April 4, 2021, respectively, and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on these foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during each of the three months ended April 3, 2022 and April 4, 2021. In addition, in connection with certain intercompany loan agreements utilized to finance its acquisitions and stock repurchase program, the Company enters into forward foreign exchange contracts intended to hedge movements in foreign exchange rates prior to settlement of such intercompany loans denominated in foreign currencies. The Company records these hedges at fair value on the Company’s condensed consolidated balance sheets. The unrealized gains and losses on these hedges, as well as the gains and losses associated with the remeasurement of the intercompany loans, are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from financing activities within the Company’s condensed consolidated statement of cash flows. The outstanding forward exchange contracts designated as economic hedges, which were intended to hedge movements in foreign exchange rates prior to the settlement of certain intercompany loan agreements included combined U.S. Dollar notional amounts of $360.2 million as of January 2, 2022, and combined U.S. Dollar notional amounts of $1,309.0 million as of April 4, 2021. The net gains and losses on these derivatives, combined with the gains and losses on the remeasurement of the hedged intercompany loans were not material for each of the three months ended April 3, 2022 and April 4, 2021. The Company paid $0.8 million and received $6.0 million during the three months ended April 3, 2022 and April 4, 2021, respectively, from the settlement of these hedges. During fiscal year 2018, the Company designated a portion of the 2026 Notes to hedge its net investments in certain foreign subsidiaries. Unrealized translation adjustments from a portion of the 2026 Notes were included in the foreign currency translation component of accumulated other comprehensive income ("AOCI"), which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. As of April 3, 2022, the total notional amount of the 2026 Notes that was designated to hedge net investments in foreign subsidiaries was €497.2 million. The unrealized foreign exchange gains recorded in AOCI related to the net investment hedge were $16.7 million and $21.6 million for the three months ended April 3, 2022 and April 4, 2021, respectively. The Company does not expect any material net pre-tax gains or losses to be reclassified from accumulated other comprehensive loss into interest and other expense, net within the next twelve months.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Apr. 03, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of April 3, 2022. The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during the three months ended April 3, 2022. The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition-related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value. Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of April 3, 2022 and January 2, 2022 classified in one of the three classifications described above: Fair Value Measurements at April 3, 2022 Using: Total Carrying Value at April 3, 2022 Quoted Prices in Significant Other Significant (In thousands) Marketable securities $ 56,683 $ 56,683 $ — $ — Foreign exchange derivative assets 229 — 229 — Foreign exchange derivative liabilities (1,258) — (1,258) — Contingent consideration (49,828) — — (49,828) Fair Value Measurements at January 2, 2022 Using: Total Carrying Value at January 2, 2022 Quoted Prices in Significant Other Significant (In thousands) Marketable securities $ 53,073 $ 53,073 $ — $ — Foreign exchange derivative assets 3,765 — 3,765 — Foreign exchange derivative liabilities (3,463) — (3,463) — Contingent consideration (57,996) — — (57,996) Level 1 and Level 2 Valuation Techniques: The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities. Marketable securities: Include equity and fixed-income securities measured at fair value using the quoted market prices in active markets at the reporting date. Foreign exchange derivative assets and liabilities: Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company's condensed consolidated balance sheet on a net basis and are recorded in other assets. As of both April 3, 2022 and January 2, 2022, none of the master netting arrangements involved collateral. Level 3 Valuation Techniques: The Company’s Level 3 liabilities are comprised of contingent consideration related to acquisitions. For liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 liabilities. Contingent consideration: Contingent consideration is measured at fair value at the acquisition date using projected milestone dates, discount rates, probabilities of success and projected revenues (for revenue-based considerations). Projected risk-adjusted contingent payments are discounted back to the current period using a discounted cash flow model. The fair values of contingent consideration are calculated on a quarterly basis based on a collaborative effort of the Company’s operations, finance and accounting groups, as appropriate. Potential valuation adjustments are made as additional information becomes available, including the progress towards achieving the revenue targets as compared to initial projections, with the impact of such adjustments being recorded in the Company's condensed consolidated statements of operations. A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: Three Months Ended April 3, April 4, (In thousands) Balance at beginning of period $ (57,996) $ (2,953) Additions (4,961) — Amounts paid and foreign currency translation 1,422 69 Adjustments recognized in goodwill 12,400 — Change in fair value (included within selling, general and administrative expenses) (693) (240) Balance at end of period $ (49,828) $ (3,124) The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1. The Company's outstanding senior unsecured notes had a fair value of $4,270.3 million and a carrying value of $4,464.3 million as of April 3, 2022. The Company's outstanding senior unsecured notes had a fair value of $4,612.8 million and a carrying value of $4,479.5 million as of January 2, 2022. The fair values of the outstanding senior unsecured notes were estimated using market quotes from brokers and were based on current rates offered for similar debt, which are Level 2 measurements. The Company’s other debt facilities, including the Company's senior revolving and term loan credit facilities, had an aggregate carrying value of $403.4 million and $504.5 million as of April 3, 2022 and January 2, 2022, respectively. The carrying value approximates fair value and were classified as Level 2.

Contingencies

Contingencies	3 Months Ended
	Apr. 03, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company’s responsibility is established and when the cost can be reasonably estimated. The Company has accrued $12.0 million and $11.9 million as of April 3, 2022 and January 2, 2022, respectively, which represents its management’s estimate of the cost of the remediation of known environmental matters and does not include any potential liability for related personal injury or property damage claims. These amounts were included in accrued expenses and other current liabilities. The Company's environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s condensed consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the condensed consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded. The Company is subject to various claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Although the Company has established accruals for potential losses that it

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Apr. 03, 2022
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue [Table Text Block]	In the following tables, revenue is disaggregated by primary geographical markets, primary end-markets and timing of revenue recognition. Reportable Segments Three Months Ended April 3, 2022 April 4, 2021 Discovery & Analytical Solutions Diagnostics Total Discovery & Analytical Solutions Diagnostics Total (In thousands) Primary geographical markets Americas $ 273,158 $ 327,936 $ 601,094 $ 175,115 $ 400,927 $ 576,042 Europe 158,238 198,168 356,406 135,458 311,743 447,201 Asia 170,970 130,972 301,942 144,036 140,410 284,446 $ 602,366 $ 657,076 $ 1,259,442 $ 454,609 $ 853,080 $ 1,307,689 Primary end-markets Diagnostics $ — $ 657,076 $ 657,076 $ — $ 853,080 $ 853,080 Life sciences 412,409 — 412,409 277,201 — 277,201 Applied markets 189,957 — 189,957 177,408 — 177,408 $ 602,366 $ 657,076 $ 1,259,442 $ 454,609 $ 853,080 $ 1,307,689 Timing of revenue recognition Products and services transferred at a point in time $ 461,314 $ 554,520 $ 1,015,834 $ 326,662 $ 615,106 $ 941,768 Services transferred over time 141,052 102,556 243,608 127,947 237,974 365,921 $ 602,366 $ 657,076 $ 1,259,442 $ 454,609 $ 853,080 $ 1,307,689

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Apr. 03, 2022
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Information [Table Text Block]	The following unaudited pro forma information presents the combined financial results for the Company and BioLegend as if the acquisition of BioLegend had been completed at the beginning of fiscal year 2020: Three Months Ended (In thousands, except per share data) Pro Forma Statement of Operations Information: Revenue $ 1,385,114 Income from continuing operations $ 370,624 Basic earnings per share: Income from continuing operations $ 2.94 Diluted earnings per share: Income from continuing operations $ 2.93

Restructuring and Lease Charg_2

Restructuring and Lease Charges, Net (Tables)	3 Months Ended
	Apr. 03, 2022
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Plan Activity [Table Text Block]	The following table summarizes the reductions in headcount, the initial restructuring or contract termination charges by reporting segment, and the dates by which payments were substantially completed, or the dates by which payments are expected to be substantially completed, for restructuring actions implemented during fiscal years 2022 and 2021: Workforce Reductions Closure of Excess Facility Total (Expected) Date Payments Substantially Completed by Headcount Reduction Discovery & Analytical Solutions Diagnostics Discovery & Analytical Solutions Diagnostics Severance Excess Facility (In thousands, except headcount data) Q1 2022 Plan 81 $ 5,832 $ 399 $ — $ — $ 6,231 Q4 FY2022 — Q4 2021 Plan 31 3,139 77 150 — 3,366 Q3 FY2022 Q1 FY2023 Q3 2021 Plan 39 420 366 — — 786 Q2 FY2022 — Q2 2021 Plan 25 968 564 — — 1,532 Q1 FY2022 — Q1 2021 Plan 77 3,941 1,615 — — 5,556 Q4 FY2021 —

Interest and Other Expense (I_2

Interest and Other Expense (Income), Net (Tables)	3 Months Ended
	Apr. 03, 2022
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and other expense, net, consisted of the following: Three Months Ended April 3, April 4, (In thousands) Interest income $ (595) $ (411) Interest expense 28,388 14,126 Change in fair value of financial securities 12,125 (19,298) Other components of net periodic pension credit (2,362) (3,719) Other income, net (311) (3,404) Total interest and other expense (income), net $ 37,245 $ (12,706)

Inventories, Net (Tables)

Inventories, Net (Tables)	3 Months Ended
	Apr. 03, 2022
Inventory Disclosure [Abstract]
Schedule of Net Inventories	Inventories consisted of the following: April 3, January 2, (In thousands) Raw materials $ 239,937 $ 229,356 Work in progress 77,667 69,744 Finished goods 328,320 325,614 Total inventories $ 645,924 $ 624,714

Debt (Tables)

Debt (Tables)	3 Months Ended
	Apr. 03, 2022
Debt Disclosure [Abstract]
Schedule of Debt	The Company’s debt consisted of the following: April 3, Outstanding Principal Unamortized Debt Discount Unamortized Debt Issuance Costs Net Carrying Amount (In thousands) Long-Term Debt: Senior Unsecured Revolving Credit Facility $ — $ — $ (3,181) $ (3,181) Unsecured Term Loan Credit Facility 400,000 — (477) 399,523 0.550% Senior Unsecured Notes due in 2023 ("2023 Notes") 500,000 (131) (1,798) 498,071 0.850% Senior Unsecured Notes due in 2024 ("2024 Notes") 800,000 (408) (4,519) 795,073 1.875% Senior Unsecured Notes due in 2026 ("2026 Notes") 551,800 (2,341) (2,155) 547,304 1.900% Senior Unsecured Notes due in 2028 ("2028 Notes") 500,000 (338) (4,078) 495,584 3.3% Senior Unsecured Notes due in 2029 ("2029 Notes") 850,000 (2,199) (6,086) 841,715 2.55% Senior Unsecured Notes due in March 2031 ("March 2031 Notes") 400,000 (123) (3,227) 396,650 2.250% Senior Unsecured Notes due in September 2031 ("September 2031 Notes") 500,000 (1,458) (4,302) 494,240 3.625% Senior Unsecured Notes due in 2051 ("2051 Notes") 400,000 (4) (4,333) 395,663 Other Debt Facilities, non-current 3,336 — — 3,336 Total Long-Term Debt $ 4,905,136 $ (7,002) $ (34,156) $ 4,863,978 Current Portion of Long-term Debt: Other Debt Facilities, current 3,729 — — 3,729 Total $ 4,908,865 $ (7,002) $ (34,156) $ 4,867,707 January 2, Outstanding Principal Unamortized Debt Discount Unamortized Debt Issuance Costs Net Carrying Amount (In thousands) Long-Term Debt: Senior Unsecured Revolving Credit Facility $ — $ — $ (3,362) $ (3,362) Unsecured Term Loan Credit Facility 500,000 (14) (658) 499,328 2023 Notes 500,000 (152) (2,093) 497,755 2024 Notes 800,000 (447) (4,945) 794,608 2026 Notes 568,600 (2,538) (2,280) 563,782 2028 Notes 500,000 (348) (4,200) 495,452 2029 Notes 850,000 (2,252) (6,234) 841,514 March 2031 Notes 400,000 (126) (3,294) 396,580 September 2031 Notes 500,000 (1,485) (4,380) 494,135 2051 Notes 400,000 (4) (4,335) 395,661 Other Debt Facilities, non-current 4,284 — — 4,284 Total Long-Term Debt $ 5,022,884 $ (7,366) $ (35,781) $ 4,979,737 Current Portion of Long-term Debt: Other Debt Facilities, current 4,240 — — 4,240 Total $ 5,027,124 $ (7,366) $ (35,781) $ 4,983,977

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Apr. 03, 2022
Earnings Per Share [Abstract]
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations	The following table reconciles the number of shares utilized in the earnings per share calculations: Three Months Ended April 3, April 4, (In thousands) Number of common shares—basic 126,137 112,028 Effect of dilutive securities: Stock options 339 359 Restricted stock awards 159 108 Number of common shares—diluted 126,635 112,495 Number of potentially dilutive securities excluded from calculation due to antidilutive impact 512 162

Industry Segment Information (T

Industry Segment Information (Tables)	3 Months Ended
	Apr. 03, 2022
Segment Reporting [Abstract]
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations	Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below: Three Months Ended April 3, April 4, (In thousands) Discovery & Analytical Solutions Product revenue $ 408,875 $ 267,255 Service revenue 193,491 187,354 Total revenue 602,366 454,609 Operating income from continuing operations 14,515 42,947 Diagnostics Product revenue 458,070 544,297 Service revenue 199,006 308,783 Total revenue 657,076 853,080 Operating income from continuing operations 258,012 441,467 Corporate Operating loss from continuing operations (17,682) (16,638) Continuing Operations Product revenue 866,945 811,552 Service revenue 392,497 496,137 Total revenue 1,259,442 1,307,689 Operating income from continuing operations 254,845 467,776 Interest and other expense (income), net 37,245 (12,706) Income from continuing operations before income taxes $ 217,600 $ 480,482

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Apr. 03, 2022
Stockholders' Equity Note [Abstract]
Components of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive loss consisted of the following: April 3, January 2, (In thousands) Foreign currency translation adjustments, net of income taxes $ (245,821) $ (161,810) Unrecognized prior service costs, net of income taxes (842) (842) Unrealized net losses on securities, net of income taxes (56) (40) Accumulated other comprehensive loss $ (246,719) $ (162,692)

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	3 Months Ended
	Apr. 03, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the three months ended April 3, 2022 were as follows: Discovery & Analytical Solutions Diagnostics Consolidated (In thousands) Balance at January 2, 2022 $ 5,446,234 $ 1,970,350 $ 7,416,584 Foreign currency translation (38,132) (13,795) (51,927) Acquisitions, earn-outs and other (1,085) 3,712 2,627 Balance at April 3, 2022 $ 5,407,017 $ 1,960,267 $ 7,367,284
Identifiable Intangible Asset Balances	Identifiable intangible asset balances by category were as follows: April 3, January 2, (In thousands) Patents $ 31,025 $ 31,033 Less: Accumulated amortization (28,742) (28,693) Net patents 2,283 2,340 Trade names and trademarks 168,225 170,983 Less: Accumulated amortization (64,762) (62,441) Net trade names and trademarks 103,463 108,542 Licenses 68,001 67,887 Less: Accumulated amortization (54,897) (54,315) Net licenses 13,104 13,572 Core technology 1,841,179 1,834,177 Less: Accumulated amortization (527,001) (494,310) Net core technology 1,314,178 1,339,867 Customer relationships 3,165,411 3,195,704 Less: Accumulated amortization (726,145) (673,425) Net customer relationships 2,439,266 2,522,279 In-process research and development — 5,920 Net amortizable intangible assets 3,872,294 3,992,520 Non-amortizing intangible asset: Trade name 70,584 70,584 Total $ 3,942,878 $ 4,063,104

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Apr. 03, 2022
Fair Value Disclosures [Abstract]
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis	The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of April 3, 2022 and January 2, 2022 classified in one of the three classifications described above: Fair Value Measurements at April 3, 2022 Using: Total Carrying Value at April 3, 2022 Quoted Prices in Significant Other Significant (In thousands) Marketable securities $ 56,683 $ 56,683 $ — $ — Foreign exchange derivative assets 229 — 229 — Foreign exchange derivative liabilities (1,258) — (1,258) — Contingent consideration (49,828) — — (49,828) Fair Value Measurements at January 2, 2022 Using: Total Carrying Value at January 2, 2022 Quoted Prices in Significant Other Significant (In thousands) Marketable securities $ 53,073 $ 53,073 $ — $ — Foreign exchange derivative assets 3,765 — 3,765 — Foreign exchange derivative liabilities (3,463) — (3,463) — Contingent consideration (57,996) — — (57,996)
Reconciliation of Beginning and Ending Level 3 Net Liabilities	A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows: Three Months Ended April 3, April 4, (In thousands) Balance at beginning of period $ (57,996) $ (2,953) Additions (4,961) — Amounts paid and foreign currency translation 1,422 69 Adjustments recognized in goodwill 12,400 — Change in fair value (included within selling, general and administrative expenses) (693) (240) Balance at end of period $ (49,828) $ (3,124)

Basis of Presentation (Basis of

Basis of Presentation (Basis of Presentation) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2022	Apr. 04, 2021	Jan. 02, 2022
Basis of Presentation [Line Items]
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ (10,636)	$ (6,849)
Operating Lease, Right-of-Use Asset	$ 201,966		$ 207,775

Revenue (Details)

Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Jul. 03, 2022	Apr. 03, 2022	Apr. 04, 2021	Mar. 31, 2022	Jan. 02, 2022
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		$ 1,259,442	$ 1,307,689
Contract with Customer, Liability, Current		171,868			$ 201,073
Contract with Customer, Liability, Revenue Recognized		(57,691)
Contract with Customer, Asset and Liability [Abstract]
Contract with Customer, Asset, Net, Current		62,211			72,117
Contract with Customer, Liability, Current		171,868			$ 201,073
Contract with Customer, Liability, Revenue Recognized		(57,691)
Unbilled Receivables Transferred To Accounts Receivables		(37,062)
Contract with Customer, Liability, Increase (Decrease)		28,486
Contract with Customer, Asset, Increase (Decrease)		27,156
Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		1,015,834	941,768
Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		243,608	365,921
Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		601,094	576,042
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		356,406	447,201
Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		301,942	284,446
Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		602,366	454,609
Discovery & Analytical Solutions [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		461,314	326,662
Discovery & Analytical Solutions [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		141,052	127,947
Discovery & Analytical Solutions [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		273,158	175,115
Discovery & Analytical Solutions [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		158,238	135,458
Discovery & Analytical Solutions [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		170,970	144,036
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		657,076	853,080
Diagnostics [Member] | Customer Concentration Risk [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		112,700	205,600
Diagnostics [Member] | California Department of Public Health [Member] | Customer Concentration Risk [Member]
Disaggregation of Revenue [Line Items]
Contract with Customer, Liability, Current				$ 126,200
Contract with Customer, Asset and Liability [Abstract]
Contract with Customer, Liability, Current				$ 126,200
Diagnostics [Member] | California Department of Public Health [Member] | Customer Concentration Risk [Member] | Forecast [Member]
Disaggregation of Revenue [Line Items]
Contract with Customer, Liability, Revenue Recognized	$ 117,800
Contract with Customer, Asset and Liability [Abstract]
Contract with Customer, Liability, Revenue Recognized	$ 117,800
Diagnostics [Member] | Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		554,520	615,106
Diagnostics [Member] | Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		102,556	237,974
Diagnostics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		327,936	400,927
Diagnostics [Member] | Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		198,168	311,743
Diagnostics [Member] | Asia [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		130,972	140,410
Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		412,409	277,201
Life Sciences [Member] | Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		412,409	277,201
Life Sciences [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		0	0
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		657,076	853,080
Diagnostics [Member] | Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		0	0
Diagnostics [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		657,076	853,080
Applied Markets [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		189,957	177,408
Applied Markets [Member] | Discovery & Analytical Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		189,957	177,408
Applied Markets [Member] | Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		$ 0	$ 0

Changes in Accounting Policies

Changes in Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2022	Apr. 04, 2021	Jan. 02, 2022	Jan. 03, 2021
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Cost of Goods and Services Sold	$ (580,211)	$ (522,543)
Selling, general and administrative expenses	334,393	251,410
Research and development expenses	76,609	60,216
Restructuring and other costs, net	13,384	5,744
Operating income (loss) from continuing operations	254,845	467,776
Nonoperating Income (Expense)	37,245	(12,706)
Provision for income taxes	40,597	101,139
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent	177,003	379,343
Loss on disposition of discontinued operations before income taxes	0	0
Cash and cash equivalents	669,755	988,234	$ 618,319
Accounts receivable, net	(941,722)		(1,023,792)
Inventories	645,924		624,714
Other current assets	(197,110)		(173,955)
Property, Plant and Equipment, Net	547,035		545,605
Intangible assets, net	3,942,878		4,063,104
Goodwill	7,367,284		7,416,584
Other assets, net	334,793		326,706
Assets	(14,848,467)		(15,000,554)
Current portion of long-term debt	3,729		4,240
Accounts payable	376,694		355,458
Accrued expenses and other current liabilities	882,628		854,046
Long-term debt	4,863,978		4,979,737
Deferred taxes and long-term liabilities	1,354,991		1,480,469
Liabilities	7,662,125		7,859,309
Preferred Stock, Value, Issued	0		0
Common Stock, Value, Issued	126,140		126,241
Capital in excess of par value	2,721,690		2,760,522
Retained earnings	4,585,231		4,417,174
Accumulated other comprehensive loss	(246,719)		(162,692)
Stockholders' Equity Attributable to Parent	7,186,342	4,002,305	7,141,245	$ 3,735,492
Liabilities and Equity	(14,848,467)		$ (15,000,554)
Discontinued Operation, Tax Effect of Discontinued Operation	41	38
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	(41)	(38)
Net income	$ 176,962	$ 379,305

Business Combinations (Narrativ

Business Combinations (Narrative) (Details)	3 Months Ended		12 Months Ended
	Apr. 03, 2022USD ($)	Apr. 04, 2021USD ($)$ / shares	Jan. 02, 2022USD ($)employeesshares	Sep. 17, 2021$ / shares	Jan. 03, 2021USD ($)
Business Acquisition [Line Items]
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions	1 year
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 49,828,000	$ 3,124,000	$ 57,996,000		$ 2,953,000
Total transaction costs	(20,500,000)	(4,400,000)
Goodwill	7,367,284,000		7,416,584,000
Business Combination, Contingent Consideration, Liability, Current	1,100,000		1,300,000
Business Combination, Contingent Consideration, Liability, Noncurrent	48,700,000		56,700,000
Interest Expense	28,388,000	14,126,000
Business Combination, Contingent Consideration, Liability	49,800,000		$ 58,000,000
Business Combination, Acquisition Related Costs	$ 20,500,000	4,400,000
Fiscal Year 2022 Acquisitions [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	5 years
Oxford Immunotec [Member]
Business Acquisition [Line Items]
Entity Number of Employees | employees			275
Foreign Currency Transaction Gain (Loss), before Tax		(5,400,000)
Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments			$ (183,000)
Business Combination, Consideration Transferred			981,698,000
Cash Acquired			(195,010,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets			72,104,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			26,507,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets			15,564,000
Cash paid to the shareholders			1,128,584,000
Business Combination, Consideration Transferred, Liabilities Incurred			2,910,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	12 years 3 months 18 days
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value	$ 45,031,000
Goodwill	550,023,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	61,960,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			981,698,000
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable			$ 0
Nexcelom Bioscience [Member]
Business Acquisition [Line Items]
Entity Number of Employees | employees			130
BioLegend [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Revenue		1,385,114,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual			$ 91,700,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual			25,800,000
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments			0
Business Combination, Consideration Transferred			5,688,964,000
Cash Acquired			(292,377,000)
Cash Acquired from Acquisition			(292,400,000)
Business Acquisition, Cost of Acquired Entity, Consideration Paid in Cash			3,300,000,000
Business Acquisition, Cost of Acquired Entity, Consideration Paid in Common Stock			2,600,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets			184,704,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			147,200,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets			$ 9,330,000
Entity Number of Employees | employees			700
Cash paid to the shareholders			$ 3,336,115,000
Business Combination, Consideration Transferred, Liabilities Incurred			$ 6,857,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			16 years 3 months 18 days
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value			$ 0
Goodwill			3,510,710,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt			38,239,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			$ 5,688,964,000
Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax		$ 370,624,000
Business Acquisition, Pro Forma Earnings Per Share, Basic | $ / shares		$ 2,940
Business Acquisition, Pro Forma Earnings Per Share, Diluted | $ / shares		$ 2,930
Business Acquisition, Share Price | $ / shares				$ 187.56
Stock Issued During Period, Shares, Acquisitions | shares			14,066,799
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable			$ 2,638,369,000
Acquisition-related stock compensation expense	7,500,000
Cash Acquired from Acquisition			292,400,000
Shandong Meizheng [Member]
Business Acquisition [Line Items]
Compensation Expense, Excluding Cost of Good and Service Sold		$ 5,400,000
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,960,267,000		1,970,350,000
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	5,407,017,000		5,446,234,000
Core Technology [Member] | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	290,089,000
Core Technology [Member] | BioLegend [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			782,400,000
Customer Relationships [Member] | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	141,670,000
Customer Relationships [Member] | BioLegend [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			1,714,800,000
Trade Names [Member] | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	39,626,000
Trade Names [Member] | BioLegend [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			38,000,000
United States of America, Dollars | Fiscal Year 2022 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments	13,500,000
United States of America, Dollars | Oxford Immunotec [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			590,900,000
United States of America, Dollars | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			1,200,000,000
United States of America, Dollars | Nexcelom Bioscience [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			267,300,000
United States of America, Dollars | BioLegend [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			5,700,000,000
United States of America, Dollars | Fiscal Year 2021 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments	$ 318,600,000
Amortization of intangible assets recognized in acquisition [Member] | BioLegend [Member]
Business Acquisition [Line Items]
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual			47,000,000
Amortization of fair value adjustment to acquired inventory [Member] | BioLegend [Member]
Business Acquisition [Line Items]
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual			$ 16,600,000

Business Combinations (Fair Val

Business Combinations (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Apr. 03, 2022	Jan. 02, 2022
Business Acquisition [Line Items]
Goodwill	$ 7,367,284	$ 7,416,584
Fiscal Year 2022 Acquisitions [Member] | United States of America, Dollars
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments	13,500
Fiscal Year 2021 Other Acquisitions [Member] | United States of America, Dollars
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments	318,600
Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid		1,128,584
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable		0
Business Combination, Consideration Transferred, Liabilities Incurred		2,910
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value	(45,031)
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments		(183)
Cash Acquired		(195,010)
Business Combination, Consideration Transferred		981,698
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets		72,104
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment		26,507
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets		15,564
Goodwill	550,023
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(86,100)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue		(1,197)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities		(4,628)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(61,960)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		981,698
Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member] | United States of America, Dollars
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments		1,200,000
BioLegend [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid		3,336,115
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable		2,638,369
Business Combination, Consideration Transferred, Liabilities Incurred		6,857
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value		0
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments		0
Cash Acquired		(292,377)
Business Combination, Consideration Transferred		5,688,964
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets		184,704
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment		147,200
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets		9,330
Goodwill		3,510,710
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total		(668,920)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue		0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities		0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt		(38,239)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		5,688,964
BioLegend [Member] | United States of America, Dollars
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments		5,700,000
Oxford Immunotec [Member] | United States of America, Dollars
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments		590,900
Nexcelom Bioscience [Member] | United States of America, Dollars
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments		267,300
Core Technology [Member] | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	290,089
Core Technology [Member] | BioLegend [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		782,400
Trade Names [Member] | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	39,626
Trade Names [Member] | BioLegend [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		38,000
Customer Relationships [Member] | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	141,670
Customer Relationships [Member] | BioLegend [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		1,714,800
License | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		0
License | BioLegend [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		8,979
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,960,267	1,970,350
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	$ 5,407,017	$ 5,446,234

Discontinued Operations (Narrat

Discontinued Operations (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2022	Apr. 04, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ (41)	$ (38)
Pre-tax gain (loss) on disposal of business unit	0	0
Discontinued Operation, Tax Effect of Discontinued Operation	$ 41	$ 38

Restructuring and Lease Charg_3

Restructuring and Lease Charges, Net (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2022	Apr. 04, 2021
Diagnostics [Member] | Contract Termination [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination net pre-tax gains	$ (400)
Discovery & Analytical Solutions [Member] | Facility Relocation [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	1,300	$ 200
Discovery & Analytical Solutions [Member] | Contract Termination [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	$ 6,300

Restructuring and Lease Charg_4

Restructuring and Lease Charges, Net (Schedule of Initial Charges) (Details) $ in Thousands	3 Months Ended
	Apr. 03, 2022USD ($)employees	Jan. 02, 2022USD ($)employees	Oct. 03, 2021USD ($)employees	Jul. 04, 2021USD ($)employees	Apr. 04, 2021USD ($)employees
Q1 2022 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated | employees	81
Restructuring and contract termination charges, net	$ 6,231
Q4 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated | employees		31
Restructuring and contract termination charges, net		$ 3,366
Q3 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated | employees			39
Restructuring and contract termination charges, net			$ 786
Q2 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated | employees				25
Restructuring and contract termination charges, net				$ 1,532
Q1 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated | employees					77
Restructuring and contract termination charges, net					$ 5,556
Diagnostics [Member] | Employee Severance [Member] | Q1 2022 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	399
Diagnostics [Member] | Employee Severance [Member] | Q4 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net		77
Diagnostics [Member] | Employee Severance [Member] | Q3 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net			366
Diagnostics [Member] | Employee Severance [Member] | Q2 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net				564
Diagnostics [Member] | Employee Severance [Member] | Q1 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net					1,615
Diagnostics [Member] | Facility Closing [Member] | Q1 2022 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	0
Diagnostics [Member] | Facility Closing [Member] | Q4 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net		0
Diagnostics [Member] | Facility Closing [Member] | Q3 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net			0
Diagnostics [Member] | Facility Closing [Member] | Q2 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net				0
Diagnostics [Member] | Facility Closing [Member] | Q1 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net					0
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q1 2022 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	5,832
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q4 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net		3,139
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q3 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net			420
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q2 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net				968
Discovery & Analytical Solutions [Member] | Employee Severance [Member] | Q1 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net					3,941
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q1 2022 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	0
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q4 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net		$ 150
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q3 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net			$ 0
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q2 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net				$ 0
Discovery & Analytical Solutions [Member] | Facility Closing [Member] | Q1 2021 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net					0
Discovery & Analytical Solutions [Member] | Facility Relocation [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and contract termination charges, net	$ 1,300				$ 200

Interest and Other Expense (I_3

Interest and Other Expense (Income), Net (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2022	Apr. 04, 2021
Other Income and Expenses [Abstract]
Interest income	$ (595)	$ (411)
Interest expense	28,388	14,126
Change in fair value of financial securities	12,125	(19,298)
Other components of net periodic pension (credit) cost	(2,362)	(3,719)
Other expense, net	(311)	(3,404)
Total interest and other expense, net	$ 37,245	$ (12,706)

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Apr. 03, 2022	Jan. 02, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 239,937	$ 229,356
Work in progress	77,667	69,744
Finished goods	328,320	325,614
Total inventories, net	$ 645,924	$ 624,714

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2022	Apr. 04, 2021
Income Tax Contingency [Line Items]
Provision for income taxes	$ 40,597	$ 101,139
Discontinued Operation, Tax Effect of Discontinued Operation	$ 41	$ 38

Debt (Details)

Debt (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2022	Apr. 04, 2021	Jan. 02, 2022
Debt Instrument, Unamortized Discount	$ (7,002)		$ (7,366)
Unamortized Debt Issuance Expense	(34,156)		(35,781)
Debt, Long-term and Short-term, Combined Amount	4,908,865		5,027,124
Long-term Debt, Gross	4,905,136		5,022,884
Repayments of Term Loan	100,000	$ 0
Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt	(4,863,978)		(4,979,737)
Debt, Long-term and Short-term, Combined Amount	4,867,707		4,983,977
2.55 Percent Senior Unsecured Notes due in 2031 [Member]
Debt Instrument, Unamortized Discount	(123)		(126)
Unamortized Debt Issuance Expense	(3,227)		(3,294)
Long-term Debt, Gross	400,000		400,000
2.55 Percent Senior Unsecured Notes due in 2031 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt	(396,650)		(396,580)
3.625 Percent Senior Unsecured Notes due in 2051 [Member]
Debt Instrument, Unamortized Discount	(4)		(4)
Unamortized Debt Issuance Expense	(4,333)		(4,335)
Long-term Debt, Gross	400,000		400,000
3.625 Percent Senior Unsecured Notes due in 2051 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt	(395,663)		(395,661)
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]
Debt Instrument, Unamortized Discount	(2,199)		(2,252)
Unamortized Debt Issuance Expense	(6,086)		(6,234)
Long-term Debt, Gross	850,000		850,000
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt	(841,715)		(841,514)
Line of Credit, Maturing September 17, 2024 [Member]
Debt Instrument, Unamortized Discount			0
Long-term Debt			(3,362)
Unamortized Debt Issuance Expense			(3,362)
Revolving credit facility outstanding balance			0
1.875 Percent Ten Year Senior Unsecured Notes [Member]
Debt Instrument, Unamortized Discount	(2,341)		(2,538)
Unamortized Debt Issuance Expense	(2,155)		(2,280)
Long-term Debt, Gross	551,800		568,600
1.875 Percent Ten Year Senior Unsecured Notes [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt	(547,304)		(563,782)
Other Debt Facilities - Current [Member]
Debt Instrument, Unamortized Discount	0		0
Other Long-term Debt, Current	3,729		4,240
Unamortized Debt Issuance Expense	0		0
Other Debt Facilities - Current [Member] | Significant Other Observable Inputs (Level 2) [Member]
Other Long-term Debt, Current	3,729		4,240
Other Debt Facilities - Non-current [Member]
Debt Instrument, Unamortized Discount	0		0
Other Long-term Debt, Noncurrent	3,336		4,284
Unamortized Debt Issuance Expense	0		0
Other Debt Facilities - Non-current [Member] | Significant Other Observable Inputs (Level 2) [Member]
Other Long-term Debt, Noncurrent	3,336		4,284
Line of Credit, Maturing August 24, 2026 [Member]
Debt Instrument, Unamortized Discount	0
Long-term Debt	(3,181)
Unamortized Debt Issuance Expense	(3,181)
Revolving credit facility outstanding balance	0
Term Loan Credit Facility Maturing 2024 [Member]
Debt Instrument, Unamortized Discount	0		(14)
Unamortized Debt Issuance Expense	(477)		(658)
Long-term Debt, Gross	400,000		500,000
Term Loan Credit Facility Maturing 2024 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt	(399,523)		(499,328)
0.550% Senior Unsecured Notes due 2023 [Member]
Debt Instrument, Unamortized Discount	(131)		(152)
Unamortized Debt Issuance Expense	(1,798)		(2,093)
Long-term Debt, Gross	500,000		500,000
0.550% Senior Unsecured Notes due 2023 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt	(498,071)		(497,755)
0.850% Senior Unsecured Notes due 2024 [Member]
Debt Instrument, Unamortized Discount	(408)		(447)
Unamortized Debt Issuance Expense	(4,519)		(4,945)
Long-term Debt, Gross	800,000		800,000
0.850% Senior Unsecured Notes due 2024 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt	(795,073)		(794,608)
1.900% Senior Unsecured Notes due 2028 [Member]
Debt Instrument, Unamortized Discount	(338)		(348)
Unamortized Debt Issuance Expense	(4,078)		(4,200)
Long-term Debt, Gross	500,000		500,000
1.900% Senior Unsecured Notes due 2028 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt	(495,584)		(495,452)
2.250% Senior Unsecured Notes due in 2031 [Member]
Debt Instrument, Unamortized Discount	(1,458)		(1,485)
Unamortized Debt Issuance Expense	(4,302)		(4,380)
Long-term Debt, Gross	500,000		500,000
2.250% Senior Unsecured Notes due in 2031 [Member] | Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt	(494,240)		(494,135)
Long-term Debt [Member]
Debt Instrument, Unamortized Discount	(7,002)		(7,366)
Unamortized Debt Issuance Expense	$ (34,156)		$ (35,781)

Earnings Per Share (Schedule of

Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details) - shares shares in Thousands	3 Months Ended
	Apr. 03, 2022	Apr. 04, 2021
Earnings Per Share [Abstract]
Number of common shares-basic	126,137	112,028
Effect of dilutive securities, Stock options	339	359
Effect of dilutive securities, Restricted stock	159	108
Number of common shares-diluted	126,635	112,495
Number of potentially dilutive securities excluded from calculation due to antidilutive impact	512	162

Industry Segment Information In

Industry Segment Information Industry Segment Information Narrative (Details)	3 Months Ended
	Apr. 03, 2022segments
Segment Reporting Information [Line Items]
Number of Operating Segment	2

Industry Segment Information (S

Industry Segment Information (Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2022	Apr. 04, 2021
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 1,259,442	$ 1,307,689
Operating income (loss) from continuing operations	254,845	467,776
Interest and other expense (income), net	37,245	(12,706)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	217,600	480,482
Product [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	866,945	811,552
Service [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	392,497	496,137
Corporate [Member]
Segment Reporting Information [Line Items]
Operating income (loss) from continuing operations	(17,682)	(16,638)
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	657,076	853,080
Operating income (loss) from continuing operations	258,012	441,467
Diagnostics [Member] | Product [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	458,070	544,297
Diagnostics [Member] | Service [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	199,006	308,783
Discovery & Analytical Solutions [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	602,366	454,609
Operating income (loss) from continuing operations	14,515	42,947
Discovery & Analytical Solutions [Member] | Product [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	408,875	267,255
Discovery & Analytical Solutions [Member] | Service [Member]
Segment Reporting Information [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 193,491	$ 187,354

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Jul. 03, 2022	Apr. 03, 2022	Jan. 02, 2022	Oct. 03, 2021	Jul. 04, 2021	Apr. 04, 2021	Jul. 31, 2020
Schedule of Shareholders' Equity [Line Items]
Repurchased Common Shares For Activity Pursuant to Equity Incentive Plans		67,107
Aggregate Cost of Repurchased Common Shares for Activity Pursuant to Equity Incentive Plans		$ 12.2
Cash dividends (per share)		$ 0.07	$ 0.07	$ 0.07	$ 0.07	$ 0.07
Dividends Payable, Amount		$ 8.8
Dividends Payable, Date Declared		Jan. 27, 2022
Repurchase Program, 07/31/2020 [Member]
Schedule of Shareholders' Equity [Line Items]
Stock Repurchase Program, Authorized Amount							$ 250
Stock Repurchase Program, Remaining Authorized Repurchase Amount		$ 144
Number of common stock repurchased in open market		240,000
Aggregate Cost of Repurchased Common Shares Under Repurchase Program		$ 43.4
Subsequent Event [Member]
Schedule of Shareholders' Equity [Line Items]
Cash dividends (per share)	$ 0.07
Dividends Payable, Date Declared	Apr. 28, 2022

Stockholders' Equity (Component

Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Thousands	Apr. 03, 2022	Jan. 02, 2022
Stockholders' Equity Note [Abstract]
Foreign currency translation adjustments, net of income taxes	$ (245,821)	$ (161,810)
Unrecognized losses and prior service costs, net of income taxes	(842)	(842)
Unrealized net losses on securities, net of income taxes	(56)	(40)
Accumulated other comprehensive loss	$ (246,719)	$ (162,692)

Stock Plans (Narrative) (Detail

Stock Plans (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2022	Apr. 04, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of common stock under stock plans	$ 1,397	$ 4,987

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net (Narrative) (Details) - USD ($) $ in Thousands	Jan. 03, 2022	Apr. 03, 2022	Apr. 04, 2021	Jan. 02, 2022
Goodwill and Intangible Assets Net [Line Items]
Goodwill		$ 7,367,284		$ 7,416,584
Total amortization expense related to finite-lived intangible assets		102,700	$ 54,200
Future Amortization Expense, Remainder of Fiscal Year		309,300
Future Amortization Expense, Year One		402,400
Future Amortization Expense, Year Two		390,900
Future Amortization Expense, Year Three		363,700
Future Amortization Expense, Year Four		350,300
Finite-Lived Intangible Assets, Net		3,872,294		3,992,520
Intangible assets, net		3,942,878		4,063,104
Impairment Testing Date	January 3, 2022
Minimum [Member]
Goodwill and Intangible Assets Net [Line Items]
Long-term terminal growth rates for reporting units	2.00%
Discount rates for reporting units	7.00%
Maximum [Member]
Goodwill and Intangible Assets Net [Line Items]
Long-term terminal growth rates for reporting units	5.00%
Discount rates for reporting units	11.50%
Patents [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		31,025		31,033
Less: Accumulated amortization		28,742		28,693
Finite-Lived Intangible Assets, Net		2,283		2,340
Trade Names And Trademarks [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		168,225		170,983
Less: Accumulated amortization		64,762		62,441
Finite-Lived Intangible Assets, Net		103,463		108,542
Licensing Agreements [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		68,001		67,887
Less: Accumulated amortization		54,897		54,315
Finite-Lived Intangible Assets, Net		13,104		13,572
Core Technology [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		1,841,179		1,834,177
Less: Accumulated amortization		527,001		494,310
Finite-Lived Intangible Assets, Net		1,314,178		1,339,867
Customer Relationships [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		3,165,411		3,195,704
Less: Accumulated amortization		726,145		673,425
Finite-Lived Intangible Assets, Net		2,439,266		2,522,279
In-process Research and Development [Member]
Goodwill and Intangible Assets Net [Line Items]
Gross amortizable intangible assets		$ 0		$ 5,920

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) $ in Thousands	3 Months Ended
	Apr. 03, 2022USD ($)
Changes in the carrying amount of goodwill
Balance at beginning of period	$ 7,416,584
Foreign currency translation	(51,927)
Goodwill, Acquisition, Earn Outs and Other Adjustments	2,627
Balance at end of period	7,367,284
Diagnostics [Member]
Changes in the carrying amount of goodwill
Balance at beginning of period	1,970,350
Foreign currency translation	(13,795)
Goodwill, Acquisition, Earn Outs and Other Adjustments	3,712
Balance at end of period	1,960,267
Discovery & Analytical Solutions [Member]
Changes in the carrying amount of goodwill
Balance at beginning of period	5,446,234
Foreign currency translation	(38,132)
Goodwill, Acquisition, Earn Outs and Other Adjustments	(1,085)
Balance at end of period	$ 5,407,017

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) - USD ($) $ in Thousands	Apr. 03, 2022	Jan. 02, 2022
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Net amortizable intangible assets	$ 3,872,294	$ 3,992,520
Intangible assets, net	3,942,878	4,063,104
Patents [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	31,025	31,033
Less: Accumulated amortization	(28,742)	(28,693)
Net amortizable intangible assets	2,283	2,340
Trade Names And Trademarks [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	168,225	170,983
Less: Accumulated amortization	(64,762)	(62,441)
Net amortizable intangible assets	103,463	108,542
Trade names and trademarks	70,584	70,584
Licensing Agreements [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	68,001	67,887
Less: Accumulated amortization	(54,897)	(54,315)
Net amortizable intangible assets	13,104	13,572
Core Technology [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	1,841,179	1,834,177
Less: Accumulated amortization	(527,001)	(494,310)
Net amortizable intangible assets	1,314,178	1,339,867
Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	3,165,411	3,195,704
Less: Accumulated amortization	(726,145)	(673,425)
Net amortizable intangible assets	2,439,266	2,522,279
In-process Research and Development [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	$ 0	$ 5,920

Derivatives And Hedging Activ_2

Derivatives And Hedging Activities (Details) $ in Thousands, € in Millions	3 Months Ended
	Apr. 03, 2022USD ($)	Apr. 03, 2022EUR (€)	Apr. 04, 2021USD ($)	Jan. 02, 2022USD ($)
Derivative [Line Items]
Company's business conducted outside United States	60.00%	60.00%
Payments for (Proceeds from) Hedge, Financing Activities	$ 762		$ (6,005)
Payments for (Proceeds from) Hedge, Excluding Pre-issuance Hedge	(800)
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net	$ 0
European And Asian Currencies [Member]
Derivative [Line Items]
Maximum maturity period for foreign exchange contracts, in months	12 months	12 months
Duration Of Foreign Currency Derivatives	30 days	30 days
Fair Value Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount	$ 376,600		969,500	$ 371,900
Notional Amount of US Dollar Derivatives [Member] | Cash Flow Hedging [Member]
Derivative [Line Items]
Derivative, Notional Amount			1,309,000	$ 360,200
Net Investment Hedging [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Derivative [Line Items]
Unrealized Gain (Loss) on Net Investment Hedge in AOCI	$ 16,700		$ 21,600
Euro Member Countries, Euro | Net Investment Hedging [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Derivative [Line Items]
Notional Amount of Nonderivative Instruments | €		€ 497.2

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) $ in Thousands, € in Millions	3 Months Ended
	Apr. 03, 2022USD ($)	Apr. 03, 2022EUR (€)	Jan. 02, 2022USD ($)	Jan. 02, 2022EUR (€)	Apr. 04, 2021USD ($)	Jan. 03, 2021USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 49,828		$ 57,996		$ 3,124	$ 2,953
Unamortized Debt Issuance Expense	34,156		35,781
Debt Instrument, Unamortized Discount	(7,002)		(7,366)
2.55 Percent Senior Unsecured Notes due in 2031 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unamortized Debt Issuance Expense	3,227		3,294
Debt Instrument, Unamortized Discount	(123)		(126)
3.625 Percent Senior Unsecured Notes due in 2051 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unamortized Debt Issuance Expense	4,333		4,335
Debt Instrument, Unamortized Discount	(4)		(4)
Line of Credit, Maturing September 17, 2024 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Revolving credit facility outstanding balance			0
Unamortized Debt Issuance Expense			3,362
Long-term Debt			3,362
Debt Instrument, Unamortized Discount			0
1.875 Percent Ten Year Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unamortized Debt Issuance Expense	2,155		2,280
Debt Instrument, Unamortized Discount	(2,341)		(2,538)
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unamortized Debt Issuance Expense	6,086		6,234
Debt Instrument, Unamortized Discount	(2,199)		(2,252)
Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured senior notes, fair value	$ 4,270,300		4,612,800
DNA Labs & Biosense [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Description	Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash.
Biosense & Sirion [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Maximum Period	6 years 8 months 12 days
Biosense, Sirion, Qognit, SonoVol & Prisms [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 111,300
Business Combination, Contingent Consideration Arrangements, Weighted Average Period	5 years 8 months 12 days
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	$ 4,863,978		4,979,737
Significant Other Observable Inputs (Level 2) [Member] | 2.55 Percent Senior Unsecured Notes due in 2031 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	396,650		396,580
Significant Other Observable Inputs (Level 2) [Member] | 3.625 Percent Senior Unsecured Notes due in 2051 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	395,663		395,661
Significant Other Observable Inputs (Level 2) [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	547,304		563,782
Significant Other Observable Inputs (Level 2) [Member] | 3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	841,715		841,514
Significant Other Observable Inputs (Level 2) [Member] | Senior Unsecured Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt	$ 4,464,300		$ 4,479,500
Significant Other Observable Inputs (Level 2) [Member] | Other Debt Facilities, including the senior revolving credit facility [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Long-term Debt | €		€ 403.4		€ 504.5

Fair Value Measurements (Assets

Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) - USD ($) $ in Thousands	Apr. 03, 2022	Jan. 02, 2022	Apr. 04, 2021	Jan. 03, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 49,828	$ 57,996	$ 3,124	$ 2,953
Fair Value, Recurring [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	56,683	53,073
Foreign exchange derivative assets, net	(229)	(3,765)
Foreign exchange derivative liabilities, net	(1,258)	(3,463)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	49,828	57,996
Fair Value, Recurring [Member] | Quoted Prices In Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	56,683	53,073
Foreign exchange derivative assets, net	0	0
Foreign exchange derivative liabilities, net	0	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	0	0
Fair Value, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Foreign exchange derivative assets, net	(229)	(3,765)
Foreign exchange derivative liabilities, net	(1,258)	(3,463)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	0	0
Fair Value, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Foreign exchange derivative assets, net	0	0
Foreign exchange derivative liabilities, net	0	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 49,828	$ 57,996

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 03, 2022	Apr. 04, 2021	Jan. 02, 2022
Fair Value Disclosures [Abstract]
Balance beginning of period	$ (57,996)	$ (2,953)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases	4,961	0
Payments	1,422	69
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3	12,400	0
Change in fair value (included within selling, general and administrative expenses)	(693)	(240)
Balance end of period	(49,828)	$ (3,124)
Business Combination, Contingent Consideration, Liability	$ (49,800)		$ (58,000)

Contingencies (Details)

Contingencies (Details) $ in Millions	3 Months Ended
	Apr. 03, 2022USD ($)years	Jan. 02, 2022USD ($)
Commitments and Contingencies Disclosure [Abstract]
Management's estimate of total cost of ultimate disposition | $	$ 12	$ 11.9
Number of years over which estimated environmental cost will be paid | years	10